Regeneron Secures Sanofi-Aventis Antibody Funding Through 2017
This article was originally published in The Pink Sheet Daily
Executive Summary
Building on an existing partnership, Regeneron may receive as much as $1.3 billion from Sanofi-Aventis through 2017 with no obligation to repay.
You may also be interested in...
Sanofi Holds Brainstorming Sessions To Fuel Its Therapeutic Strategy Units
Just two years after Sanofi-Aventis SA set out to reinvent itself as the flexible, entrepreneurial, easy-partnering, globally diversified health care leader of the future, the French pharma has mounted a grassroots campaign to familiarize the academic/biotech community with its new Therapeutic Strategy Units, a handful of targeted areas with high unmet need and commensurately huge opportunity that are part of Sanofi's long-range R&D strategy.
Sanofi Holds Brainstorming Sessions To Fuel Its Therapeutic Strategy Units
Just two years after Sanofi-Aventis SA set out to reinvent itself as the flexible, entrepreneurial, easy-partnering, globally diversified health care leader of the future, the French pharma has mounted a grassroots campaign to familiarize the academic/biotech community with its new Therapeutic Strategy Units, a handful of targeted areas with high unmet need and commensurately huge opportunity that are part of Sanofi's long-range R&D strategy.
Reenergizing R&D: Sanofi Stirs The Pot, But Does It Have The Recipe?
Sanofi-Aventis SA spent the past year culling drug candidates and reorganizing its research group in an attempt to shape up a shoddy pipeline. Now, though the company is in the midst of a hostile bid to acquire the biotech Genzyme – an acquisition attempt spurred by the fact the French drug maker doesn't have enough new drugs to make up for the ones it is losing to generics – management maintains that the reorganized research group is on track to become one of the most productive in the industry.